阿加曲班用于肝素相关性血小板减少症患者PCI术抗凝治疗1例并文献复习

Argatroban Anticoagulation During Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia:One Case Report and Review of Literature

目的:探讨肝素相关性血小板减少症(heparin-induced thrombocytopenia,HIT)患者行经皮冠状动脉介入治疗(percutaneoustransluminal coronary intervention,PCI)术中及术后使用阿加曲班进行抗凝的效果及安全性。方法:报道并回顾性分析阿加曲班用于肝素相关性血小板减少症患者PCI术一例并进行文献复习。结果:患者女性,55岁,皮下注射低分子肝素4天后血小板由140×109/L下降为17×109/L,患者出现牙龈出血、左前臂出现瘀斑,诊断为HIT。行冠状动脉支架植入术术中及术后使用阿加曲班抗凝,未出现出血及血栓事件。结论:肝素相关性血小板减少症患者行PCI术,术中及术后采用阿加曲班进行抗凝治疗是有效安全的。

Objective：To study the effiency and safety of argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia（HIT）.Methods： One case of argatroban anticoagulation during PCI in Patients With HIT was reported with its related literature reviewed.Results： The patient was a 55-year old female whose blood platelet was reduced from 140×109/L to 17×109/L with gingival bleeding and bruisesafter on the left forearm after subcutaneous injection of Low-Molecular-Weight Heparins four days,and was diagnosed HIT.No bleeding and thrombotic events happened when preoperative and postoperative using of argatroban for PCI.Conclusion： Argatroban can be used as an anticoagulant agent for PCI in patients with HIT.